Hemab Therapeutics Holdings, Inc. (NASDAQ: COAG)
One-Sentence Summary of Key Findings
Hemab Therapeutics is a clinical-stage biotechnology company focused on novel prophylactic antibody therapies for rare underserved bleeding disorders, with strong recent clinical data presentations, multiple analyst upgrades to Strong Buy ratings with price targets around $50, a successful May 2026 IPO, and substantial cash runway post-IPO, though as a pre-revenue biotech it carries typical high-risk clinical and commercialization uncertainties.
Stock Performance and Company Financials
Stock Performance
- IPO Details (Fact): Priced at $18.00 per share on April 30, 2026; upsized offering of 19.26 million shares (including full greenshoe) raising gross proceeds of approximately $346.7 million; began trading on Nasdaq Global Select Market under ticker COAG on or around May 1, 2026.Yahoo Finance GlobeNewswire
- Post-IPO Performance (Fact): Significant appreciation since IPO, with reports of first-day close around $34 (88.89% gain) and continued gains leading to 52-week range approximately $18–$52; YTD returns reported as high as 82%+ in some snapshots, substantially outperforming S&P 500 benchmarks in available periods.Yahoo Finance IPOScoop
- Recent Volatility (Fact): Notable single-day moves, including +10.69% on one reported trading day; average daily volume around 300k–350k shares post-IPO.Yahoo Finance
- Data Limitation: Extremely limited trading history (only since May 2026 IPO); performance metrics like multi-year returns are not meaningful or are placeholder/not applicable; historical data may be sparse on some platforms.
Company Financials
Overview (Fact): Pre-revenue clinical-stage company with no product sales; operating expenses driven by R&D for pipeline advancement. Fiscal year ends December 31.
| Metric | Value/Details | Source/Notes |
|---|
| Cash Position (as of Mar 31, 2026) | $163.5 million (cash, equivalents, marketable securities) | Pre-IPO; Yahoo Finance / Q1 report |
| Post-IPO Cash Runway | Fund operating expenses and capex into 2029 (including ~$317M net IPO proceeds) | Company statement; BioSpace |
| Q1 2026 Net Loss | $22.7 million ($23.98 per share) vs. $15.3M prior year | Yahoo Finance / GlobeNewswire |
| TTM Net Income / EPS | Approximately -$71.3 million / -$10.13 (diluted) | Yahoo Finance |
| Market Cap (recent) | Approximately $2.3 billion | Yahoo Finance |
| Employees | Approximately 59 (full-time) | Yahoo Finance |
| Other | No dividends; PE/forward metrics N/A or negative due to losses | Standard for clinical-stage biotech |
Interpretation: Strong capitalization from IPO and prior Series C ($157M in Oct 2025) positions the company well for Phase 3 trials and pipeline expansion without immediate dilution pressure.
Uncertainty: Future cash burn will accelerate with pivotal trials; success depends on clinical outcomes and potential partnerships.
Data Limitation/Assumption: Financials based on Q1 2026 reports and IPO disclosures; full annual 2025/2026 audited statements limited as recent public company; no revenue guidance or detailed segment reporting available yet.
More Information: Company Investor Relations | Yahoo Finance Financials | Nasdaq Profile
Analyst Ratings
Consensus (Fact): Strong Buy / Moderate Buy rating from 5 analysts as of mid-July 2026; average 12-month price target approximately $48–$50 (range $36–$55).
| Firm | Rating | Price Target | Action/Date | Notes |
|---|
| Wedbush | Outperform / Buy | $55 (raised from $42) | July 13, 2026 | Strong HMB-002 data |
| Jefferies | Buy | $47 (raised from $39) | July 13, 2026 | Maintain |
| H.C. Wainwright | Buy | $52 (raised from $40) | July 13, 2026 | Positive updates |
| Evercore ISI | Outperform | Around $46–50 range (initiated May 2026) | May 2026 | Pipeline potential |
| Goldman Sachs | Buy | Lower end (~$36 initial) | May 2026 | VWD opportunity |
- Recent Drivers (Fact): Multiple upgrades and target raises following positive clinical data presentations at ISTH 2026 Congress on sutacimig (HMB-001) and HMB-002.Yahoo Finance Investing.com
- Interpretation: Analysts view the differentiated bispecific/monovalent antibody approaches and data on bleed reduction (e.g., durable responses in GT and VWD) as supportive of multi-billion dollar peak sales potential in underserved indications.
- Uncertainty: Ratings and targets are forward-looking opinions subject to change with new trial data, regulatory feedback, or market conditions; low analyst coverage typical for newer IPOs.
More Information: Yahoo Finance Analysts | MarketBeat | Benzinga Ratings
Customers and Competitors
Customers / Target Market
- Primary Focus (Fact): Patients with rare bleeding disorders lacking adequate prophylactic options, including Glanzmann thrombasthenia (GT), Factor VII deficiency, Von Willebrand Disease (VWD), and potentially heavy menstrual bleeding (via HMB-003).
- Market Context (Fact): Millions worldwide affected by serious bleeding disorders; emphasis on "All Patients Matter" philosophy for those with limited current treatments (often on-demand rather than preventive).
- Interpretation: No commercial customers yet (clinical-stage); future revenue from payers, hospitals, and specialty pharmacies treating these orphan/rare disease populations if approved.
- Uncertainty: Actual addressable market size depends on trial success, label, pricing, and reimbursement; recruitment challenges noted in rare disease trials.
Competitors
Competitive Landscape (Fact): Focuses on prophylactic innovation in coagulation disorders where options are limited; competes with established players in VWD and other bleeding disorders, plus emerging biotechs in gene therapy or novel mechanisms.
| Competitor | Focus / Relevance | Notes |
|---|
| Star Therapeutics | VWD and related | Emerging player in similar space |
| Roche / larger pharma (e.g., Takeda, CSL, Octapharma) | VWD treatments, factor replacements | Established players with existing products |
| uniQure, Spark Therapeutics (Roche) | Gene therapies for bleeding disorders | Alternative modality (one-time treatment vs. ongoing prophylaxis) |
| Jazz Pharmaceuticals, Blueprint Medicines, Sana Biotechnology (broader examples) | Biotech peers in hematology/oncology or related | Indirect competition for capital/talent |
- Interpretation: Hemab's bispecific antibody platform (e.g., sutacimig) and subcutaneous options aim to differentiate via convenience and efficacy in prophylaxis for hard-to-treat indications.
- Uncertainty: Competitive dynamics could shift with new entrants, gene therapy approvals, or acquisitions; detailed head-to-head data limited.
More Information: Hemab Website (Therapeutic Focus) | PitchBook Competitors | Tracxn Analysis
Additional Sections (Company Overview, History, Recent News)
Company Overview
Clinical-stage biotechnology company (founded 2020, headquartered Cambridge, MA with Denmark operations) developing targeted therapies for blood coagulation disorders. Pipeline led by sutacimig (HMB-001, bispecific antibody) in Phase 2/3 for GT and FVII deficiency; HMB-002 (monovalent antibody) in Phase 1/2 for VWD; preclinical assets including HMB-003. Single operating segment in R&D.Yahoo Finance Hemab.com
Company History
- 2020: Founded.
- Oct 2025: $157M Series C financing (led by Sofinnova, with participation from major investors) to advance pipeline toward registration studies.
- May 2026: Upsized IPO on Nasdaq.
- 2026: Multiple positive data readouts at ISTH Congress; Breakthrough Therapy designation noted in some reports; ongoing enrollment in studies (e.g., VELORA trials).
More Information: IR Site | News & Presentations
Recent News Highlights
- July 2026: Presentations of clinical/preclinical data on sutacimig and HMB-002 at ISTH 2026 Congress; analyst PT raises.
- May 2026: Q1 financials and IPO closing.
- June 2026: Pipeline updates and conference participation.
More Information: Yahoo News | StockTitan
Overall Data Limitations and Assumptions: Information synthesized from public sources as of mid-July 2026; stock prices and exact recent quotes excluded per guidelines. Biotech investments involve high uncertainty around clinical trial success (e.g., Phase 3 outcomes), regulatory approval, manufacturing, competition, and market adoption. Financial projections and analyst targets are opinions, not guarantees. Verify all data with primary sources like SEC filings, company press releases, and official exchanges. No investment advice intended.